United States Cell Expansion Market to Hit $16.5 Billion by 2031, Driven by Biotechnology & Regenerative Medicine

Leander, Texas and Tokyo, Japan - Dec.09.2025
As per DataM intelligence research report" Global Cell Expansion Market reached US$ 20 billion in 2023 and is expected to reach US$ 55 billion by 2031, growing at a CAGR of 15.3% during the forecast period 2024-2031." Cell therapy development and regenerative medicine are driving advancements in cell expansion technologies.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/cell-expansion-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, Thermo Fisher Scientific launched the "HyPerforma" bioreactor specifically for T-cell expansion. The system offers precise control over gas and nutrient exchange to maximize cell viability. It supports the scaling of CAR-T therapies in the U.S.

✅ In October 2025, Corning Life Sciences introduced a new dissolvable microcarrier for adherent cell culture. The technology simplifies the harvest of stem cells by eliminating the need for separation steps. It streamlines the manufacturing workflow for U.S. regenerative medicine.

✅ In September 2025, Repligen acquired a fluid management startup to enhance its cell expansion portfolio. The acquisition adds advanced perfusion technology to their single-use systems. It helps U.S. biopharma increase yield in high-density cell cultures.

✅ In August 2025, Berkeley Lights (PhenomeX) released a platform for selecting high-growth cell lines using optofluidics. The tool identifies the most productive cells for expansion early in the process. It accelerates cell line development for U.S. biotech companies.

Japan: Recent Industry Developments

✅ In December 2025, Fujifilm Irvine Scientific opened a new cell culture media plant in Saitama. The facility produces specialized media for expanding iPS cells and immune cells. It secures the domestic supply chain for Japan's thriving cell therapy sector.

✅ In November 2025, Hitachi High-Tech launched an automated cell culture system for clinical use. The closed system performs media exchange and passage without human intervention. It reduces contamination risk and labor costs in Japanese hospitals.

✅ In October 2025, Kaneka Corporation developed a new scaffold material for expanding mesenchymal stem cells. The 3D structure mimics the in-vivo environment to maintain cell potency. It improves the therapeutic quality of cells produced in Japan.

✅ In September 2025, ReproCELL announced a partnership to contract manufacture iPS cells for global clients. The partnership leverages Japan's regulatory framework for expedited regenerative medicine. It positions Japan as a global hub for cell expansion services.

Cell Expansion Market: Drivers
The cell expansion market is rapidly expanding with growth in cell therapy, regenerative medicine, and biologics manufacturing where scalable, high-quality cell culture processes are critical. Technologies for adherent and suspension cell expansion-including bioreactors, microcarriers, and perfusion systems-are evolving to meet demands for higher cell densities, reproducibility, and GMP compliance. Automation, closed-system processing, and real-time monitoring enhance scalability while reducing contamination risk and batch variability. As cell-based therapeutics move from clinical to commercial scale, process intensification and cost reduction remain strategic imperatives.

Supplier ecosystems involving cell culture media, single-use bioreactors, sensors, and process analytics are co-innovating to streamline scale-up. Regulatory expectations for product characterization, potency assays, and process validation drive investment in quality systems. Partnerships between contract development and manufacturing organizations (CDMOs) and biotech firms are accelerating commercialization timelines. With continued clinical momentum and demand for advanced therapies, the cell expansion market is set for substantial growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cell-expansion-market?Prasad

Cell Expansion Market: Major Players
Thermo Fisher Scientific, Inc, Merck KGaA, Becton, Dickinson and Company, GE Healthcare, Terumo BCT, Beckman Coulter Inc, Miltenyi Biotec, Stemcell Technologies, Inc., Takara Bio Inc., Lnza Group LTD among others.

Segment Covered in the Cell Expansion Market:
By Product Type
The market is segmented into automated cell expansion systems 35%, instruments 25%, consumables 25%, and bioreactors 15%, with automated systems dominating due to efficiency, reproducibility, and demand in regenerative medicine and stem cell research. Instruments and consumables support routine cell culture and laboratory operations. Bioreactors are growing in large-scale production and vaccine development. Rising adoption of advanced cell culture technologies drives growth across all product types.

By Cell Type
Cell types include animal cells 20%, human cells 30%, stem cells 25%, adult stem cells 15%, and others 10%, with human cells dominating due to applications in regenerative therapies and clinical studies. Stem cells and adult stem cells are widely used in research and therapeutic applications. Animal cells are important for preclinical studies and biopharmaceutical production. Growing research and clinical applications fuel market adoption across all cell types.

By Application
Applications include regenerative medicine and stem cell research 35%, cancer & cell-based research 25%, clinical studies 15%, vaccine production 15%, and others 10%, with regenerative medicine and stem cell research dominating due to high investment in therapies and personalized medicine. Cancer and cell-based research are growing with increasing oncology studies. Vaccine production is expanding due to rising demand and cell-based platforms. Broad research and clinical focus supports adoption.

By End-User
End-users include biopharmaceutical & biotechnology companies 35%, research institutes 25%, hospitals 20%, diagnostic laboratories 10%, and others 10%, with biopharma and biotech leading due to R&D and commercial production activities. Research institutes support academic and preclinical studies. Hospitals adopt cell expansion for clinical trials and therapies. Diagnostic labs contribute to disease modeling and cellular research.

Regional Analysis
North America - 40% Share
North America leads with 40% share driven by high R&D investment, regenerative medicine initiatives, and stem cell research in the U.S. and Canada. Automated systems and human cells dominate. Regenerative medicine and cancer research are key applications. Biopharmaceutical and biotech companies lead end-user adoption. Advanced healthcare infrastructure supports market growth.

Europe - 25% Share
Europe holds 25% share due to increasing investment in cell therapy, academic research, and biotechnology hubs in Germany, UK, France, and Switzerland. Automated systems and human cells dominate. Regenerative medicine and cancer research are leading applications. Biopharma companies and research institutes are primary end-users. Government funding and regulatory support encourage market expansion.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share driven by increasing biotech research, vaccine production, and clinical trials in China, India, Japan, and Australia. Automated systems dominate. Stem cells and human cells are widely adopted. Regenerative medicine and vaccine production lead applications. Biopharmaceutical companies and research institutes are key end-users. Rising healthcare infrastructure supports growth.

Latin America - 7% Share
Latin America holds 7% share due to growing research investment, stem cell programs, and biopharmaceutical activities in Brazil, Mexico, and Argentina. Automated systems dominate. Human and stem cells are widely used. Regenerative medicine and cancer research are major applications. Biopharmaceutical companies and hospitals are primary end-users. Academic and clinical research initiatives support growth.

Middle East - 5% Share
The Middle East records 5% share driven by growing investment in biotechnology, clinical research, and healthcare infrastructure in UAE, Saudi Arabia, and Qatar. Automated systems dominate. Human and stem cells are widely adopted. Regenerative medicine and clinical studies are key applications. Biopharmaceutical companies and hospitals lead adoption. Government initiatives support market expansion.

Africa - 3% Share
Africa holds 3% share due to limited but emerging biotechnology research and clinical applications in South Africa, Nigeria, and Egypt. Automated systems dominate. Human and stem cells are primary cell types. Regenerative medicine and research applications lead. Biopharma companies and research institutes are key end-users. Increasing awareness and research funding drive gradual adoption.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=cell-expansion-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.